Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OmniMSC-AMI in STEMI Patients Undergoing Primary PCI
NCT05724576Phase 1Terminated
- Sponsor
- Taiwan Bio Therapeutics
- Start
- Jun 2023
- Primary completion
- May 2026
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of OmniMSC-AMI in ST-segment elevation myocardial infarction (STEMI) (2 arms), sponsored by Taiwan Bio Therapeutics. Primary endpoint: Number of participants with treatment-related adverse events at 30 days. Started Jun 2023; status: terminated.
02
Drugs
OmniMSC-AMI
03
Conditions
ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT05724576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05724576.